The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.
Adjuvants: Classification,Modus Operandi, and Licensing
Open accessAbstract
Vaccination is one of the most efficient strategies for the prevention of infectious diseases. Although safer, subunit vaccines are poorly immunogenic and for this reason the use of adjuvants is strongly recommended. Since their discovery in the beginning of the 20th century, adjuvants have been used to improve immune responses that ultimately lead to protection against disease. The choice of the adjuvant is of utmost importance as it can stimulate protective immunity. Their mechanisms of action have now been revealed. Our increasing understanding of the immune system, and of correlates of protection, is helping in the development of new vaccine formulations for global infections. Nevertheless, few adjuvants are licensed for human vaccines and several formulations are now being evaluated in clinical trials. In this review, we briefly describe the most well known adjuvants used in experimental and clinical settings based on their main mechanisms of action and also highlight the requirements for licensing new vaccine formulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K. J., et al. (2006) · Nature · doi:10.1038/nature04734 · Cited by 3,888 · cited 1×
“Indeed, MF59 is able to stimulate macrophages, resident monocytes, and DCs to secrete several chemokines like CCL4, CCL2, CCL5, and CXCL8 that in turn induce leukocyte recruitment and antigen uptake leading to migration to lymph nodes and triggering the adaptative immune response [32, 38, 39].”
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection
Girardin, S. E., Boneca, I. G., Viala, J., Chamaillard, M., Labigne, A., Thomas, G., Philpott, D. J., & Sansonetti, P. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200651200 · Cited by 2,408
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008) · Nature · doi:10.1038/nature06939 · Cited by 1,542
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,419
Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S.-N., Apter, D. L., Kitchener, H. C., Castellsague, X., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60946-5 · Cited by 1,315
The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus
Zhao, Y., Yang, J., Shi, J., Gong, Y.-N., Lu, Q., Xu, H., Liu, L., & Shao, F. (2011) · Nature · doi:10.1038/nature10510 · Cited by 1,270
Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., & Lanzavecchia, A. (2005) · Nature Immunology · doi:10.1038/ni1223 · Cited by 1,157
Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives
Ellouz, F., Adam, A., Ciorbaru, R., & Lederer, E. (1974) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(74)90458-6 · Cited by 1,019
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 993
Programming the magnitude and persistence of antibody responses with innate immunity
Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., Kwissa, M., et al. (2011) · Nature · doi:10.1038/nature09737 · Cited by 975
Toll-like receptor 3 promotes cross-priming to virus-infected cells
Schulz, O., Diebold, S. S., Chen, M., Näslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y.-T., Flavell, R. A., Liljeström, P., & Reis e Sousa, C. (2005) · Nature · doi:10.1038/nature03326 · Cited by 921
Belshe, R. B., Mendelman, P. M., Treanor, J., King, J., Gruber, W. C., Piedra, P., Bernstein, D. I., Hayden, F. G., Kotloff, K., Zangwill, K., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382002 · Cited by 916
The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., & Mitchell, T. C. (2007) · Science · doi:10.1126/science.1138963 · Cited by 896
Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity
Kofoed, E. M., & Vance, R. E. (2011) · Nature · doi:10.1038/nature10394 · Cited by 891
Towards an understanding of the adjuvant action of aluminium
Marrack, P., McKee, A. S., & Munks, M. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2510 · Cited by 887
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848
Jurk, M., Heil, F., Vollmer, J., Schetter, C., Krieg, A. M., Wagner, H., Lipford, G., & Bauer, S. (2002) · Nature Immunology · doi:10.1038/ni0602-499 · Cited by 838
Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon
Le Bon, A., Etchart, N., Rossmann, C., Ashton, M., Hou, S., Gewert, D., Borrow, P., & Tough, D. F. (2003) · Nature Immunology · doi:10.1038/ni978 · Cited by 818
Applications of nanotechnology for immunology
Smith, D. M., Simon, J. K., & Baker Jr, J. R. (2013) · Nature Reviews Immunology · doi:10.1038/nri3488 · Cited by 767
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Mechanisms of Action of Adjuvants
Awate, S., Babiuk, L. A., & Mutwiri, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00114 · Cited by 732
Adjuvants—a classification and review of their modes of action
Cox, J. C., & Coulter, A. R. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00183-1 · Cited by 682
Longhi, M. P., Trumpfheller, C., Idoyaga, J., Caskey, M., Matos, I., Kluger, C., Salazar, A. M., Colonna, M., & Steinman, R. M. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090247 · Cited by 663
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Pasquale, A., Preiss, S., Silva, F., & Garçon, N. (2015) · Vaccines · doi:10.3390/vaccines3020320 · Cited by 648
The perfect mix: recent progress in adjuvant research
Guy, B. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1681 · Cited by 620
Modes of action of Freund's adjuvants in experimental models of autoimmune diseases
Billiau, A., & Matthys, P. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.70.6.849 · Cited by 617
Vollmer, J., Weeratna, R., Payette, P., Jurk, M., Schetter, C., Laucht, M., Wader, T., Tluk, S., Liu, M., Davis, H. L., et al. (2004) · European Journal of Immunology · doi:10.1002/eji.200324032 · Cited by 595
Kushnir, N., Streatfield, S. J., & Yusibov, V. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 587
Targeting the innate immune response with improved vaccine adjuvants
Pashine, A., Valiante, N. M., & Ulmer, J. B. (2005) · Nature Medicine · doi:10.1038/nm1210 · Cited by 555
Querec, T., Bennouna, S., Alkan, S., Laouar, Y., Gorden, K., Flavell, R., Akira, S., Ahmed, R., & Pulendran, B. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051720 · Cited by 552
Biodegradable nanoparticles for cytosolic delivery of therapeutics
VASIR, J., & LABHASETWAR, V (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.003 · Cited by 526
Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600120 · Cited by 524
Molecular and cellular signatures of human vaccine adjuvants
Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., O'Hagan, D., Rappuoli, R., & De Gregorio, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804699105 · Cited by 492
Aluminium compounds for use in vaccines
Lindblad, E. B. (2004) · Immunology & Cell Biology · doi:10.1111/j.0818-9641.2004.01286.x · Cited by 488
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Morel, S., Didierlaurent, A., Bourguignon, P., Delhaye, S., Baras, B., Jacob, V., Planty, C., Elouahabi, A., Harvengt, P., & Carlsen, H. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.011 · Cited by 476
Use of defined TLR ligands as adjuvants within human vaccines
Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437
Seubert, A., Monaci, E., Pizza, M., O’Hagan, D. T., & Wack, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5402 · Cited by 430
Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
O’Neill, L. A. J., Bryant, C. E., & Doyle, S. L. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001073 · Cited by 427
Shen, H., Ackerman, A. L., Cody, V., Giodini, A., Hinson, E. R., Cresswell, P., Edelson, R. L., Saltzman, W. M., & Hanlon, D. J. (2006) · Immunology · doi:10.1111/j.1365-2567.2005.02268.x · Cited by 420
Immunological notes. XVII–XXIV
Glenny, A. T., Pope, C. G., Waddington, H., & Wallace, U. (1926) · The Journal of Pathology and Bacteriology · doi:10.1002/path.1700290106 · Cited by 399
Recent Advances of Vaccine Adjuvants for Infectious Diseases
Lee, S., & Nguyen, M. T. (2015) · Immune Network · doi:10.4110/in.2015.15.2.51 · Cited by 385
Mechanism of action of clinically approved adjuvants
Lambrecht, B. N., Kool, M., Willart, M. A., & Hammad, H. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.01.004 · Cited by 354
Dickinson, B. L., & Clements, J. D. (1995) · Infection and Immunity · doi:10.1128/iai.63.5.1617-1623.1995 · Cited by 350
Garçon, N., Vaughn, D. W., & Didierlaurent, A. M. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.192 · Cited by 347
Hemmi, H., Kaisho, T., Takeda, K., & Akira, S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3059 · Cited by 340
Adjuvant Properties of Aluminum and Calcium Compounds
Gupta, R. K., Rost, B. E., Relyveld, E., & Siber, G. R. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_8 · Cited by 330
Immunological concepts of vaccine adjuvant activity
Schijns, V. E. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00120-5 · Cited by 330
Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children
Vesikari, T., Knuf, M., Wutzler, P., Karvonen, A., Kieninger-Baum, D., Schmitt, H.-J., Baehner, F., Borkowski, A., Tsai, T. F., & Clemens, R. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010331 · Cited by 317
Liu, C., Lou, Y., Lizée, G., Qin, H., Liu, S., Rabinovich, B., Kim, G. J., Wang, Y.-H., Ye, Y., Sikora, A. G., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33583 · Cited by 316
The history of MF59 ® adjuvant: a phoenix that arose from the ashes
O’Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R., & Giudice, G. D. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.140 · Cited by 313
Trumpfheller, C., Caskey, M., Nchinda, G., Longhi, M. P., Mizenina, O., Huang, Y., Schlesinger, S. J., Colonna, M., & Steinman, R. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711976105 · Cited by 310
Huleatt, J. W., Jacobs, A. R., Tang, J., Desai, P., Kopp, E. B., Huang, Y., Song, L., Nakaar, V., & Powell, T. J. (2007) · Vaccine · doi:10.1016/j.vaccine.2006.08.013 · Cited by 299
Hartmann, G., Battiany, J., Poeck, H., Wagner, M., Kerkmann, M., Lubenow, N., Rothenfusser, S., & Endres, S. (2003) · European Journal of Immunology · doi:10.1002/eji.200323813 · Cited by 296
Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs
Felnerova, D., Viret, J.-F., Glück, R., & Moser, C. (2004) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2004.10.005 · Cited by 296
Turley, C. B., Rupp, R. E., Johnson, C., Taylor, D. N., Wolfson, J., Tussey, L., Kavita, U., Stanberry, L., & Shaw, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.041 · Cited by 294
Loré, K., Betts, M. R., Brenchley, J. M., Kuruppu, J., Khojasteh, S., Perfetto, S., Roederer, M., Seder, R. A., & Koup, R. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4320 · Cited by 291
Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J. M., Zambon, M. C., & Katz, J. M. (2005) · The Journal of Infectious Diseases · doi:10.1086/428948 · Cited by 285
Cruz, L. J., Tacken, P. J., Fokkink, R., Joosten, B., Stuart, M. C., Albericio, F., Torensma, R., & Figdor, C. G. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.02.013 · Cited by 281
Douce, G., Turcotte, C., Cropley, I., Roberts, M., Pizza, M., Domenghini, M., Rappuoli, R., & Dougan, G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1644 · Cited by 278
Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming
Gagliardi, M. C., Sallusto, F., Marinaro, M., Langenkamp, A., Lanzavecchia, A., & De Magistris, M. T. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(2000)30:8<2394::aid-immu2394>3.0.co;2-y · Cited by 278
Recent Advances in Vaccine Adjuvants
Singh, M., & O'Hagan, D. T. (2002) · Pharmaceutical Research · doi:10.1023/a:1016104910582 · Cited by 245
Antigen depot is not required for alum adjuvanticity
Hutchison, S., Benson, R. A., Gibson, V. B., Pollock, A. H., Garside, P., & Brewer, J. M. (2012) · The FASEB Journal · doi:10.1096/fj.11-184556 · Cited by 244
Thomas, C., Rawat, A., Hope-Weeks, L., & Ahsan, F. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100255c · Cited by 241
Self‐administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum
Hengge, U. R., Esser, S., Schultewolter, T., Behrendt, C., Meyer, T., Stockfleth, E., & Goos, M. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03777.x · Cited by 232
Kapikian, A. Z., Hoshino, Y., Chanock, R. M., & Perez-Schael, I. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/174.supplement_1.s65 · Cited by 207
Prins, R. M., Craft, N., Bruhn, K. W., Khan-Farooqi, H., Koya, R. C., Stripecke, R., Miller, J. F., & Liau, L. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.157 · Cited by 203
Stahl-Hennig, C., Eisenblätter, M., Jasny, E., Rzehak, T., Tenner-Racz, K., Trumpfheller, C., Salazar, A. M., Überla, K., Nieto, K., Kleinschmidt, J., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000373 · Cited by 198
Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant
Vesikari, T., Pellegrini, M., Karvonen, A., Groth, N., Borkowski, A., O'Hagan, D. T., & Podda, A. (2009) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31819d6394 · Cited by 190
Imiquimod and resiquimod as novel immunomodulators
Dockrell, D. H. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.6.751 · Cited by 185
Smirnov, D., Schmidt, J. J., Capecchi, J. T., & Wightman, P. D. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.061 · Cited by 174
Marchetti, M., Rossi, M., Giannelli, V., Giuliani, M. M., Pizza, M., Censini, S., Covacci, A., Massari, P., Pagliaccia, C., & Manetti, R. (1998) · Vaccine · doi:10.1016/s0264-410x(97)00153-9 · Cited by 170
TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)
Weeratna, R. D., Makinen, S. R., McCluskie, M. J., & Davis, H. L. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.06.024 · Cited by 170
Toll-Like Receptor Agonists: Are They Good Adjuvants?
Gnjatic, S., Sawhney, N. B., & Bhardwaj, N. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eaca65 · Cited by 165
The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination
Vono, M., Taccone, M., Caccin, P., Gallotta, M., Donvito, G., Falzoni, S., Palmieri, E., Pallaoro, M., Rappuoli, R., Di Virgilio, F., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319784110 · Cited by 164
The March Toward Malaria Vaccines
Hoffman, S. L., Vekemans, J., Richie, T. L., & Duffy, P. E. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.09.011 · Cited by 164
Structure−Activity Relationships in Human Toll-Like Receptor 7-Active Imidazoquinoline Analogues
Shukla, N. M., Malladi, S. S., Mutz, C. A., Balakrishna, R., & David, S. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100358c · Cited by 163
Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants
Olive, C. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.189 · Cited by 162
“Pathogen-Mimicking” Nanoparticles for Vaccine Delivery to Dendritic Cells
Elamanchili, P., Lutsiak, C. M. E., Hamdy, S. I., Diwan, M., & Samuel, J. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31802cf3e3 · Cited by 160
Nakaya, H. I., Clutterbuck, E., Kazmin, D., Wang, L., Cortese, M., Bosinger, S. E., Patel, N. B., Zak, D. E., Aderem, A., Dong, T., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519690113 · Cited by 159
Vaccine Adjuvants: Mode of Action
Gregorio, E. D., Caproni, E., & Ulmer, J. B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00214 · Cited by 154
Tewari, K., Flynn, B., Boscardin, S., Kastenmueller, K., Salazar, A., Anderson, C., Soundarapandian, V., Ahumada, A., Keler, T., Hoffman, S., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.098 · Cited by 153
Self-citationMucosal vaccine adjuvants update
Rhee, J. H., Lee, S. E., & Kim, S. Y. (2012) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2012.1.1.50 · Cited by 151
Ghimire, T. R., Benson, R. A., Garside, P., & Brewer, J. M. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.06.002 · Cited by 149
Garaude, J., Kent, A., van Rooijen, N., & Blander, J. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002868 · Cited by 147
Morse, M. A., Chapman, R., Powderly, J. D., Blackwell, K., Keler, T., Green, J., Riggs, R., He, L.-Z., Ramakrishna, V., Vitale, L. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0891 · Cited by 142
Halperin, S. A., Dobson, S., McNeil, S., Langley, J. M., Smith, B. R., McCall-Sani, R., Levitt, D., Nest, G. V., Gennevois, D., & Eiden, J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.095 · Cited by 134
Flagellin-induced NLRC4 phosphorylation primes the inflammasome for activation by NAIP5
Matusiak, M., Opdenbosch, N. V., Walle, L. V., Sirard, J., Kanneganti, T., & Lamkanfi, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417945112 · Cited by 134
Taylor, D. N., Treanor, J. J., Sheldon, E. A., Johnson, C., Umlauf, S., Song, L., Kavita, U., Liu, G., Tussey, L., Ozer, K., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.086 · Cited by 132
Ruane, D., Chorny, A., Lee, H., Faith, J. J., Pandey, G. S., Shan, M., Simchoni, N., Rahman, A. H., Garg, A., Weinstein, E. G., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150567 · Cited by 128
de Jong, S. D., Chikh, G., Sekirov, L., Raney, S. G., Semple, S. C., Klimuk, S. K., Yuan, N., Hope, M., Cullis, P. R., & Tam, Y. K. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0276-x · Cited by 127
Expression of toll-like receptors on B lymphocytes
Dasari, P., Nicholson, I., Hodge, G. L., Dandie, G. W., & Zola, H. (2005) · Cellular Immunology · doi:10.1016/j.cellimm.2005.08.020 · Cited by 126
Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice
Dupuis, M. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00263-7 · Cited by 123
Ghosh, T. K., Mickelson, D. J., Fink, J. R., Solberg, J. C., Inglefield, J. R., Hook, D. J., Gupta, S. K., Gibson, S. J., & Alkan, Ş. Ş. (2006) · Cellular Immunology · doi:10.1016/j.cellimm.2006.12.002 · Cited by 120
Lipid based particulate formulations for the delivery of antigen
Copland, M. J., Rades, T., Davies, N. M., & Baird, M. A. (2005) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01315.x · Cited by 118
Topical pharmacotherapy for skin cancer
Micali, G., Lacarrubba, F., Nasca, M. R., Ferraro, S., & Schwartz, R. A. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.12.037 · Cited by 116
Mark, K. E., Corey, L., Meng, T., Magaret, A., Huang, M.-L. W., Selke, S., Slade, H. B., Tyring, S. K., Warren, T. J., Sacks, S. L., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/513276 · Cited by 112
Ebola and Marburg virus-like particles activate human myeloid dendritic cells
Bosio, C. M., Moore, B. D., Warfield, K. L., Ruthel, G. T., Mohamadzadeh, M., Aman, M. J., & Bavari, S. (2004) · Virology · doi:10.1016/j.virol.2004.05.025 · Cited by 111
Manish, M., Rahi, A., Kaur, M., Bhatnagar, R., & Singh, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061885 · Cited by 108
Henriques, H. R., Rampazo, E. V., Gonçalves, A. J. S., Vicentin, E. C. M., Amorim, J. H., Panatieri, R. H., Amorim, K. N. D. S., Yamamoto, M. M., Ferreira, L. C. D. S., Alves, A. M. B., et al. (2013) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002330 · Cited by 107
Self-citationDavey, G. M., Wojtasiak, M., Proietto, A. I., Carbone, F., Heath, W. R., & Bedoui, S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903013 · Cited by 103
Heineman, T. C., Clements-Mann, M. L., Poland, G. A., Jacobson, R. M., Izu, A. E., Sakamoto, D., Eiden, J., Nest, G. A. V., & Hsu, H. H. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00088-2 · Cited by 103
Nagato, T., Lee, Y.-R., Harabuchi, Y., & Celis, E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2781 · Cited by 103
Use of CpG oligodeoxynucleotides as immunoprotective agents
Klinman, D. M. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.6.937 · Cited by 100
Ryan, E. J., McNeela, E. A., Murphy, G. A., Stewart, H., O’Hagan, D. T., Pizza, M., Rappuoli, R., & Mills, K. H. G. (1999) · Infection and Immunity · doi:10.1128/iai.67.12.6270-6280.1999 · Cited by 98
Leenaars, M., Hendriksen, C. F. M., de Leeuw, W. A., Carat, F., Delahaut, P., Fischer, R. W., Halder, M., Hanly, W. C., Hartinger, J., Hau, J., et al. (1999) · Alternatives to Laboratory Animals · doi:10.1177/026119299902700106 · Cited by 94
Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy
Barry, M. A., & Cooper, C. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.11.1731 · Cited by 93
Histopathological Studies of Reactions in Mice Injected with Aluminum‐Adsorbed Tetanus Toxoid
Goto, N., & Akama, K. (1982) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1982.tb00261.x · Cited by 91
O’Hagan, D. T., Wack, A., & Podda, A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100402 · Cited by 90
Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines
Savelkoul, H. F. J., Ferro, V. A., Strioga, M. M., & Schijns, V. E. C. J. (2015) · Vaccines · doi:10.3390/vaccines3010148 · Cited by 89
Immunostimulating reconstituted influenza virosomes
Zurbriggen, R. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00541-8 · Cited by 84
Kaumaya, P. T. P., Foy, K. C., Garrett, J. T., Rawale, S. V., Vicari, D., Thurmond, J. M., Lamb, T., Mani, A., Kane, Y., Balint, C. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3883 · Cited by 83
Bernstein, D. I., Harrison, C. J., Tomai, M. A., & Miller, R. L. (2001) · The Journal of Infectious Diseases · doi:10.1086/319262 · Cited by 82
Beaudette, T. T., Bachelder, E. M., Cohen, J. A., Obermeyer, A. C., Broaders, K. E., Fréchet, J. M. J., Kang, E.-S., Mende, I., Tseng, W. W., Davidson, M. G., et al. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900038e · Cited by 79
Immunization Against Bacterial Diseases of the Intestine
Levine, M. M. (2000) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200010000-00003 · Cited by 76
Díez‐Domingo, J., Garcés‐Sánchez, M., Baldó, J.-M., Planelles, M. V., Ubeda, I., Jubert, A., Marés, J., Moris, P., Garcı́a-Corbeira, P., Dramé, M., et al. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181daf921 · Cited by 76
TLR9-Dependent Induction of Intestinal α-Defensins by Toxoplasma gondii
Foureau, D., Mielcarz, D. W., Menard, L. C., Schulthess, J., Werts, C., Vasseur, V., Ryffel, B., Kasper, L. H., & Buzoni–Gatel, D. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901642 · Cited by 72
A prophylactic hepatitis B vaccine with a novel adjuvant system
Thoelen, S., Clercq, N. D., & Tornieporth, N. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00462-x · Cited by 71
The Ultra-Potent and Selective TLR8 Agonist VTX-294 Activates Human Newborn and Adult Leukocytes
Dowling, D. J., Tan, Z. W., Prokopowicz, Z. M., Palmer, C. D., Matthews, M.-A. H., Dietsch, G. N., Hershberg, R. M., & Levy, O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058164 · Cited by 69
The Immune Response Modifier Resiquimod Mimics CD40-Induced B Cell Activation
Bishop, G. A., Ramirez, L. M., Baccam, M., Busch, L. K., Pederson, L. K., & Tomai, M. A. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1769 · Cited by 68
AN EXPERIMENTAL STUDY OF PROTECTIVE INOCULATION WITH HEAT KILLED TUBERCLE BACILLI
Opie, E. L., & Freund, J. (1937) · The Journal of Experimental Medicine · doi:10.1084/jem.66.6.761 · Cited by 68
Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines
Leroux-Roels, G. G., Leroux‐Roels, I., Clément, F., Ofori‐Anyinam, O., Lievens, M., Jongert, E., Moris, P., Ballou, W. R., & Cohen, J. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29375 · Cited by 66
Jakobsen, H., Schulz, D., Pizza, M., Rappuoli, R., & Jónsdóttir, I. (1999) · Infection and Immunity · doi:10.1128/iai.67.11.5892-5897.1999 · Cited by 65
Dalba, C., Bellier, B., Kasahara, N., & Klatzmann, D. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300054 · Cited by 64
MÜSSENER, Å., Klareskog, L., Lorentzen, J. C., & Kleinau, S. (1995) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1995.tb03635.x · Cited by 58
Adjuvant synergy: The effects of nasal coadministration of adjuvants
Moschos, S. A., Bramwell, V., Somavarapu, S., & Alpar, H. O. (2004) · Immunology and Cell Biology · doi:10.1111/j.0818-9641.2004.01280.x · Cited by 55
Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine
Gong, Y., Tao, L., Wang, F., LIU, W., Jing, L., LIU, D., HU, S., Xie, Y., & Zhou, N. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3950 · Cited by 54
Oldfield, V., Keating, G. M., & Perry, C. M. (2005) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200506030-00006 · Cited by 50
Fife, K. H., Meng, T., Ferris, D. G., & Liu, P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01173-07 · Cited by 50
Revisiting Freund's incomplete adjuvant for vaccines in the developing world
Miller, L. H., Saul, A. J., & Mahanty, S. (2005) · Trends in Parasitology · doi:10.1016/j.pt.2005.07.005 · Cited by 46
Fernandez, É. M., Chang, J., Fontaine, J., Bialecki, E., Rodriguez, F., Werkmeister, E., Krieger, V., Ehret, C., Heurtault, B., Fournel, S., et al. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.04.068 · Cited by 46
Huret, C., Desjardins, D., Miyalou, M., Levacher, B., Zin, M. A., Bonduelle, O., Combadière, B., Dalba, C., Klatzmann, D., & Bellier, B. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.025 · Cited by 40
Barackman, J. D., Ott, G. S., Pine, S. O., & O’Hagan, D. T. (2001) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.8.3.652-657.2001 · Cited by 39
O’Hagan, D. T., Goldbeck, C., Ugozzoli, M., Ott, G. S., & Burke, R. L. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00009-2 · Cited by 35
Kim, E. H., Kim, J. H., Samivel, R., Bae, J.-S., Chung, Y., Chung, P., Lee, S. E., & Mo, J. (2016) · Allergy · doi:10.1111/all.12839 · Cited by 35
Lentivirus-Based Virus-Like Particles as a New Protein Delivery Tool
Muratori, C., Bona, R., & Federico, M. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-533-0_7 · Cited by 32
Marshall, J. D. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg700 · Cited by 32
Ruane, D., Do, Y., Brane, L., Garg, A., Bozzacco, L., Kraus, T., Caskey, M. F., Salazar, A. Μ., Trumpheller, C., & Mehandru, S. (2016) · Mucosal Immunology · doi:10.1038/mi.2015.133 · Cited by 25
Wu, C. C. N., Crain, B., Yao, S., Sabet, M., Lao, F. S., Tawatao, R. I., Chan, M., Smee, D. F., Julander, J. G., Cottam, H. B., et al. (2013) · Journal of Innate Immunity · doi:10.1159/000355217 · Cited by 22
Bajaj, A., Gupta, S., Pandey, R. K., Misra, K., Rastogi, S. C., & Chatterji, A. R. (1997) · Contact Dermatitis · doi:10.1111/j.1600-0536.1997.tb02479.x · Cited by 20
Martínez, A. C., de la Cueva, I. S., Boutet, P., Abeele, C. V., Smolenov, I. V., & Devaster, J. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28743 · Cited by 13
The US Food and Drug Administration Provides a Pathway for Licensing Vaccines for Global Diseases
Brennan, M. J. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000095 · Cited by 11
Cited by
Designing spatial and temporal control of vaccine responses
Roth, G. A., Picece, V. C. T. M., Ou, B. S., Luo, W., Pulendran, B., & Appel, E. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00372-2 · Cited by 316
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Facciolà, A., Visalli, G., Laganà, A., & Di Pietro, A. (2022) · Vaccines · doi:10.3390/vaccines10050819 · Cited by 316
Manganese salts function as potent adjuvants
Zhang, R., Wang, C., Guan, Y., Wei, X., Sha, M., Yi, M., Jing, M., Lv, M., Guo, W., Xu, J., et al. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00669-w · Cited by 313
Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
Zhou, H., Ma, Y., Liu, F., Li, B., Qiao, D., Ren, P., & Wang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1255799 · Cited by 46
Metadata
- Authors
- Apostólico, J. D. S., Lunardelli, V. A. S., Coirada, F. C., Boscardin, S. B., & Rosa, D. S.
- Venue
- Journal of Immunology Research
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-16
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- OpenAlex
- W2345713210
- Cited by
- 287
- References
- 148
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.